Description

Perjeta (Pertuzumab) 420mg/14mL Injection in Pakistan – Uses, Dosage, Side Effects, Price & Availability

Perjeta (Pertuzumab) is an advanced targeted therapy used in the treatment of HER2-positive breast cancer. Manufactured by Roche/Genentech, it is supplied as a 420 mg/14 mL concentrate for solution for infusion (30 mg/mL). In Pakistan, Perjeta is available on import and prescribed only under the supervision of an oncologist.

Key Product Details

• Brand Name: Perjeta

• Generic Name: Pertuzumab

• Formulation: Concentrate for solution for infusion

• Strength: 420 mg per 14 mL vial (30 mg/mL)

• Manufacturer: Roche (Imported)

• Storage: 2°C – 8°C (Refrigerated, do not freeze, protect from light)

Medical Uses of Perjeta

Perjeta is indicated in combination with Trastuzumab (Herceptin) and Docetaxel for:

• HER2-positive metastatic breast cancer (first-line treatment in patients not previously treated with anti-HER2 therapy or chemotherapy).

• Early-stage HER2-positive breast cancer, including neoadjuvant (before surgery) and adjuvant (after surgery) settings.

How Perjeta Works (Mechanism of Action)

• HER2 Blockade: Perjeta binds to subdomain II of the HER2 receptor, preventing dimerization with other HER family receptors (HER3, HER4).

• Dual Targeting with Trastuzumab: Together, they provide a dual HER2 blockade, enhancing treatment effectiveness.

• Immune Response Activation: Stimulates antibody-dependent cellular cytotoxicity (ADCC), helping the immune system attack cancer cells.

Dosage & Administration

• Initial Dose (Loading): 840 mg IV infusion over 60 minutes.

• Maintenance Dose: 420 mg IV every 3 weeks, over 30–60 minutes.

• Combination Therapy:

  • Trastuzumab: 8 mg/kg loading, then 6 mg/kg every 3 weeks.

  • Docetaxel: 75 mg/m² (can be increased to 100 mg/m² if tolerated).

• Re-administration: If more than 6 weeks pass between doses, restart with an 840 mg loading dose.

⚠️ Perjeta must only be administered by qualified healthcare professionals. It should never be given as an IV bolus.

Clinical Benefits (Backed by Trials)

• Improves overall survival (OS) and progression-free survival (PFS) – proven in the CLEOPATRA trial.

• Effective in metastatic and early-stage HER2+ breast cancer.

• Dual blockade therapy improves treatment outcomes compared to trastuzumab alone.